Business Context and Reporting Period
The supplied filing is Owens & Minor, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014—not a filing identified in its text as Accendra Health Inc. Owens & Minor distributes medical and surgical supplies and provides healthcare logistics services through Domestic and International segments. The financial figures below are in U.S. dollars; unless noted otherwise, dollar amounts are in millions.
Financial Performance
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Net revenue | $2,256.4 | $2,246.4 | +0.4% |
| Gross margin | $281.2; 12.46% of revenue | $279.1; 12.42% | +0.8% |
| Operating earnings, GAAP | $46.3 | $47.9 | -3.3% |
| Net income | $25.5 | $26.1 | -2.3% |
| Diluted EPS | $0.41 | $0.41 | Unchanged |
| Operating cash flow | $93.2 | $154.6 | -$61.4 |
- SG&A increased 3.6% to $225.6 million, or 10.00% of revenue versus 9.69%. GAAP operating margin was approximately 2.05%, compared with 2.13%; net margin was approximately 1.13%, compared with 1.16%.
- Management’s non-GAAP adjusted operating earnings were $49.5 million (2.20% of revenue) versus $49.9 million (2.22%); adjusted net income was $27.7 million versus $27.6 million, and adjusted diluted EPS was $0.44 in both periods. These measures exclude acquisition-related and exit and realignment charges.
- Cash used for investing was $12.2 million, including $7.3 million of property and equipment additions and $6.9 million of software and intangible additions, partly offset by $1.9 million from an investment sale. Financing used $0.8 million. Cash increased $80.5 million to $182.4 million; the quarter included a $20.6 million bank overdraft related to payment and collection timing.
- At March 31, cash was $182.4 million, current assets $1,768.9 million and current liabilities $1,025.5 million (current ratio approximately 1.73). Long-term debt, excluding current portion, was $214.8 million. The $200 million senior notes mature in April 2016 and bear 6.35% interest. The company had no revolver borrowings and $345 million available under its $350 million facility, net of letters of credit; it reported compliance with debt covenants.
- Quarterly dividends declared were $0.25 per share, up from $0.24. The company repurchased 142,904 shares for $5.0 million at an average $34.99 per share under a new $100 million authorization, with approximately $95 million remaining.
Material Changes and Segment Results
- Domestic revenue declined 0.3% to $2,148.9 million, reflecting lower healthcare utilization and the rationalization of smaller, less profitable customers and suppliers. Domestic operating earnings were $52.7 million, down slightly from $52.9 million; this figure includes a $5.3 million legal settlement recovery.
- International revenue increased 17.2% to $107.5 million, driven mainly by fee-for-service growth and favorable foreign exchange. International operating loss widened to $3.2 million from $3.0 million. Higher International salaries and delivery costs, including onboarding for a significant new U.K. customer, contributed to increased SG&A.
- Consolidated gross margin improved modestly, with an $11.4 million increase in International gross margin largely offset by weaker Domestic results, including lower benefits from supplier price changes and lower margins on new and renewed contracts.
- Operating cash flow fell year over year, which management attributed primarily to routine working-capital timing. In the prior-year quarter, cash flow benefited from larger changes in accounts payable and other working-capital items.
- The company revised prior-year International revenue and cost of goods sold presentation for certain contracts, reducing each by $29.3 million; the change did not affect gross margin, operating earnings, net income or cash flow.
Outlook, Commentary, and Risks
- No quantitative revenue or earnings guidance is provided. Management expects approximately $2.2 million of additional exit and realignment charges during the remainder of 2014 for activities initiated in the Domestic segment.
- Management believes cash generated from operations and available revolving credit will be sufficient for working capital, capital expenditures, debt and lease payments, dividends, repurchases and other needs. It anticipates continuing quarterly dividends, subject to Board discretion and business conditions.
- Management identified continued healthcare utilization and cost-containment pressures, customer and supplier concentration, pricing and competitive pressure, supplier funding and purchasing terms, execution of strategic initiatives, acquisition integration (including Movianto), international and foreign-exchange risks, fuel costs, information-system and data-security risks, regulatory and tax changes, and litigation as risks to results.
- The company is assessing the effect of IRS regulations on inventory costs and tax LIFO accounting; a change could make a related deferred tax liability payable and affect future cash flow. Foreign cash and short-term investments totaled $18.9 million; repatriation could result in additional taxes.
- Contingent customer performance payments totaled $1.0 million, but none were accrued because management did not consider payment probable. Outstanding Movianto acquisition and transition issues with the former owner remained under review; outcomes could not be estimated. The filing reported no material developments in previously disclosed legal proceedings or material changes to previously reported risk factors.
Important Facts to Verify
- Filing identity: Confirm whether the intended issuer is Owens & Minor, Inc.; the supplied filing text does not identify Accendra Health Inc.
- Earnings quality: Assess the effect of the $5.3 million legal recovery and other operating income on reported operating earnings, and compare GAAP results with management’s adjusted measures.
- Cash-flow sustainability: Review the working-capital timing behind the year-over-year operating cash-flow decline and the quarter-end bank overdraft.
- Segment execution: Monitor Domestic revenue and margins, and whether International growth and onboarding of the U.K. customer improve segment profitability.
- Debt, tax, and contingencies: Track the 2016 senior-note maturity, revolver covenant headroom, potential tax-LIFO cash consequences, and the unresolved Movianto matters.